Hal Buch, MD
Gastroenterology · Kingston, NYNPI 1780649574
Payments from drug & device makers
Across 81 payments — averaging $121.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$8K
- AbbVie$405
- QOL Medical, LLC$184
- Ironwood Pharmaceuticals, Inc$130
- Takeda Pharmaceuticals U.S.A., Inc.$91
- Bristol Myers Squibb$88
- plus $567 from 13 others
What the payments were for
- Food & beverage$1,46515%
- Other$8,37785%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $8,377 |
| AbbVie(2 entities) | 26 | $405 |
| QOL Medical, LLC | 8 | $184 |
| Ironwood Pharmaceuticals, Inc | 6 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $91 |
| Bristol Myers Squibb | 5 | $88 |
| UCB, Inc. | 5 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Redhill Biopharma Inc. | 3 | $48 |
| Gilead | 3 | $47 |
| Johnson & Johnson | 1 | $47 |
| Intercept Pharmaceuticals, Inc. | 2 | $42 |
| Alfasigma USA, Inc. | 2 | $39 |
| Ardelyx, Inc. | 1 | $34 |
| Medtronic | 1 | $29 |
| Braintree Laboratories, Inc. | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 2 | $23 |
| Madrigal Pharmaceuticals | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,841 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexlansoprazole DrDexlansoprazole | 50 | $15,676 |
| Famotidine | 244 | $4,491 |
| Omeprazole | 342 | $4,094 |
| Pantoprazole Sodium | 102 | $1,452 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 27 | $726 |
| Lansoprazole | 27 | $699 |
| Esomeprazole Magnesium | 14 | $491 |
| Metronidazole | 11 | $81 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Kingston
- Michael GerdisYonkers$11.9M
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Igor GrosmanBrooklyn$2.8M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.